Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Search
Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Respiratory
Respiratory
Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas
Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards
USDA & BI Expand Research Opportunities | Boehringer Ingelheim US
Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Shelter Revamps Make for Strong Bonds, More Adoptions
Shelter Revamps Make for Strong Bonds, More Adoptions
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Get in touch
Get in touch
Financial year 2018
Financial year 2018
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Swine Vaccine Combo for Two Diseases | Boehringer Ingelheim US
Click here to read more on the launch of the Boehringer Ingelheim innovative vaccine combination, protecting US swine from two viruses in one shot.
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
How Simulation is Changing the Game in Biotherapeutic Drug Development
How Simulation is Changing the Game in Biotherapeutic Drug Development
KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD
Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.